Conmed (CNMD) Tops Q2 EPS by 27c ; Offers Guidance

Conmed (NYSE: CNMD) reported Q2 EPS of $1.38, $0.27 better than the analyst estimate of $1.11. Revenue for the quarter came in at $343.5 million versus the consensus estimate of $337.46 million.

GUIDANCE:

Conmed sees FY2026 EPS of $4.48-$4.60, versus the consensus of $4.34. Conmed sees FY2026 revenue of $1.36-1.37 billion, versus the consensus of $1.36 billion.

For earnings history and earnings-related data on Conmed (CNMD) click here.

You May Also Be Interested In

• BofA maintains underperform ratings on six BDC stocks
• Nuvectis Pharma (NVCT) files $200M mixed shelf
• OBOOK Holdings posts $18.8M net loss as OwlPay Harbor volume rises